SCHEDULE: Woodline Partners Reports 3.3% Stake in Adicet Bio

Woodline Partners LP has disclosed beneficial ownership of 313,124 shares, representing 3.3% of Adicet Bio, Inc.'s common stock, as of March 31, 2026.

Summary

• Woodline Partners LP, acting as the investment adviser to Woodline Master Fund LP, has filed a Schedule 13G indicating beneficial ownership of Adicet Bio, Inc. common stock.
• The filing reports ownership of 313,124 shares of common stock.
• This ownership stake represents 3.3% of the total outstanding shares of Adicet Bio, Inc.
• The filing is an amendment (Amendment No. 1) to a previous filing.
• The reporting person is identified as an investment adviser.
• The shares are held directly by the Woodline Fund.
• The filing does not suggest any intent to influence or change the control of Adicet Bio, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data for Adicet Bio, Inc.

Positives

• Woodline Partners LP has taken a significant stake, indicating confidence in Adicet Bio's potential.
• The 3.3% ownership is a notable position for an investment adviser.
• The filing is current as of March 31, 2026, providing up-to-date information.

Negatives

• The filing does not contain any negative financial information or performance indicators as it is a Schedule 13G, which focuses on beneficial ownership.
• No specific details are provided regarding the rationale behind the investment beyond standard investment advisory activities.

Risks

• As a Schedule 13G filing, it does not detail specific risks related to Adicet Bio's business operations or the investment itself.
• The primary risk for Woodline Partners would be the general market and company-specific risks associated with investing in Adicet Bio's common stock, which are not elaborated upon in this document.

Future Outlook

This filing is a Schedule 13G and does not contain forward-looking statements or guidance from Adicet Bio, Inc. It solely reports beneficial ownership by Woodline Partners LP.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Woodline Partners LP's filing indicates a notable investment in the biotechnology sector, specifically in Adicet Bio, Inc., which operates in the cell therapy space.

Comparison to Industry Standards

• As a Schedule 13G filing, it does not provide performance metrics for comparison against industry standards.
• The 3.3% ownership stake is a common threshold for institutional investors to report under SEC regulations, but its significance relative to other investors in Adicet Bio is not detailed in this document.

Stakeholder Impact

• Shareholders: The filing informs existing shareholders about a significant institutional investor's stake, which could be perceived positively or neutrally depending on market sentiment towards Woodline Partners LP.
• Management: The company's management is aware of Woodline Partners LP's ownership, which may influence future strategic communications.
• Potential Investors: This filing provides transparency regarding ownership structure, aiding potential investors in their due diligence.

Next Steps

• Woodline Partners LP will continue to monitor its investment in Adicet Bio, Inc.
• Further filings may be required if Woodline Partners LP's ownership stake changes significantly.

Key Dates

Keywords

Adicet Bio, Schedule 13G, Woodline Partners LP, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, 3.3% Stake